PARPi potentiates with current conventional therapy in MLL leukemia

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Acute myeloid leukemias (AML) with MLL fusion proteins present a significant clinical challenge due to poor prognosis and treatment resistance.
• Conventional chemotherapies and DNA methyltransferase (DNMT) inhibitors have limited efficacy as monotherapies for MLL-rearranged leukemias.

Purpose of the Study:

• To investigate the potential of olaparib in combination with conventional chemotherapy or DNMT inhibitors to overcome treatment resistance in MLL-rearranged AML.
• To elucidate the mechanisms underlying the synergistic effects of combined olaparib treatment.

Main Methods:

• Utilized primary mouse MLL-AF9 leukemia cells and a human MLL-AF9 leukemic cell line.
• Assessed the effects of olaparib, DNMT inhibitors, and chemotherapies, both individually and in combination, on cell growth, colony formation, cell cycle progression, and apoptosis.
• Quantified DNA damage using γH2AX foci and double-strand break assays.

Main Results:

• Combined treatment with olaparib and DNMT inhibitors or chemotherapy significantly reduced leukemia cell growth and colony formation compared to single-agent treatments.
• The combination therapy induced cell cycle arrest and apoptosis in MLL-AF9 leukemic cells.
• A marked increase in DNA double-strand breaks, indicated by elevated γH2AX foci, was observed in cells treated with the combination therapy, suggesting a mechanistic basis for synergy.

Conclusions:

• Olaparib potentiates the efficacy of conventional chemotherapy and DNMT inhibitors against MLL-rearranged AML.
• The combination of olaparib with these agents offers a promising therapeutic strategy for refractory MLL leukemias.
• Enhanced DNA damage and apoptosis are key mechanisms driving the observed synergistic effects.